Actively Recruiting
Study of the Tangent Tricuspid Annular Therapy System for Repairing Severe Functional Tricuspid Regurgitation Using a Transcatheter Device
Led by Tangent Cardiovascular Inc. · Updated on 2026-10-13
25
Participants Needed
1
Research Sites
56 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and technical success of the Tangent Tricuspid Annular Therapy System in patients with severe, symptomatic functional tricuspid regurgitation. This trial focuses on adults aged 18 to 90 who have this condition despite optimal medical treatment, aiming to assess the devices performance and safety in a multi-center, single-arm study. Participants will receive treatment with the Tangent Tricuspid Annular Therapy System, a transcatheter device designed to repair the tricuspid valve. The study will measure primary safety and technical efficacy endpoints immediately after the procedure and at hospital discharge, along with secondary performance measures. During the study, participants will be monitored for major adverse events up to 30 days after the procedure. Functional status, quality of life, walking ability, and tricuspid regurgitation severity will be assessed at 30, 90, 180, and 365 days post-procedure. Participants must agree to attend all required follow-up visits to evaluate these outcomes and ensure ongoing safety monitoring throughout the study duration.
CONDITIONS
Brief Title
Safety and Feasibility Study: Transcatheter Valve Repair in Severe Symptomatic Functional Tricuspid Regurgitation
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here